Related Experiment Video
Updated: Jun 2, 2026
08:47
Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
Published on: February 10, 2012
Common polymorphisms in FMO1 are associated with nicotine dependence.
Anthony L Hinrichs1, Sharon E Murphy, Jen C Wang
1Departments of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63119, USA. tony@fire.wustl.edu
Pharmacogenetics and Genomics
|May 5, 2011
Summary
Genetic variations in the FMO1 gene are linked to nicotine dependence. This discovery may lead to better smoking cessation strategies by understanding nicotine metabolism.
Area of Science:
- Genetics
- Pharmacology
- Molecular Biology
Background:
- Tobacco use is a leading cause of preventable death globally.
- Understanding the genetic basis of nicotine addiction is crucial for improving smoking cessation success rates.
- Nicotine addiction contributes significantly to public health burdens.
Purpose of the Study:
- To identify genetic polymorphisms associated with nicotine dependence.
- To investigate the role of enzyme families involved in nicotine metabolism.
Main Methods:
- Conducted a genetic association study focusing on cytochrome P450 enzymes, flavin-containing monooxygenases (FMOs), and UDP-glucuronosyl transferases.
- Utilized discovery and independent replication samples to validate findings.
- Performed in-vitro experiments to characterize enzyme activity.
Main Results:
- Identified significant associations between FMO1 gene polymorphisms, particularly rs10912765, and nicotine dependence.
- Demonstrated that FMO1 is a more efficient catalyst of nicotine N-oxidation compared to FMO3.
- Confirmed FMO1 expression in both the kidney and brain, suggesting roles in drug metabolism and nicotine concentration.
Conclusions:
- Polymorphisms in the FMO1 gene represent significant risk factors for developing nicotine dependence.
- The mechanism likely involves variations in nicotine pharmacology and metabolism.
- These findings offer potential targets for novel smoking cessation interventions.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...